Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform

Mesoblast Ltd (NASDAQ:MESO) is among the best Australian stocks to buy in 2026. On April 14, Mesoblast Ltd (NASDAQ:MESO) announced that it has secured exclusive global rights to a patented technology platform from Mayo Clinic. This platform uses chimeric antigen receptors, and it helps improve the performance of mesenchymal lineage stromal cell (MSC) therapeutic products.

Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform

Source:unsplash

The company said the platform is designed to help mesenchymal stromal cells to better locate and act on inflamed tissue. Mesoblast plans to use the technology to sharpen the ability of its therapies to more precisely and effectively target areas of disease, increase immune response, and support tissue regeneration.

With this platform, Mesoblast sees an opportunity to generate therapies for diseases such as ulcerative colitis and Crohn’s disease. Moreover, the company sees potential for therapies for other immune disorders with the CAR technology platform in its grasp.

The CAR technology platform was developed by scientists at Mayo Clinic, and the license was held by a startup formed by Mayo Clinic. Mesoblast acquired that startup to secure the exclusive rights to the platform. Mayo Clinic will continue to support Mesoblast in advancing the technology and products tied to the platform.

Mesoblast paid for the license acquisition with its shares, though the financial details of the transaction were not disclosed.

Mesoblast Ltd (NASDAQ:MESO) is an Australian biotech company founded in 2004 and based in Melbourne. The company develops treatments for a variety of health problems, including inflammatory ailments, cardiovascular disease, and back pain.

While we acknowledge the risk and potential of MESO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MESO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Falling Stocks to Invest In Now and 10 Best 52-Week High US Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.